| Literature DB >> 31666093 |
Eva Isaksson1, Per Wester2,3, Ann Charlotte Laska2, Per Näsman4, Erik Lundström5.
Abstract
BACKGROUND: Many randomised controlled trials (RCT) fail to meet their recruitment goals. Study personnel play a key role in recruitment. The aim of this study was to identify successful strategies that study personnel consider to be important in patient recruitment to RCT.Entities:
Keywords: Questionnaire; RCT; Randomised controlled trials; Recruitment; Survey
Mesh:
Year: 2019 PMID: 31666093 PMCID: PMC6822437 DOI: 10.1186/s13063-019-3737-1
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 1The process of developing the questionnaire
Fig. 2A question in the questionnaire
Baseline characteristics of the participants
| Characteristics | |
|---|---|
| Age, year, mean (SD) | 47 years (11 years) |
| Female n (%) | 98 (71%) |
| Physicians, n (%) | 72 (53%) |
| Nurses, n (%) | 65 (47%) |
| Experience of clinical trials | |
| Very experienced* | 13 (9%) |
| Quite experienced** | 34 (25%) |
| Very inexperienced*** | 91 (66%) |
| Type of centre | |
| Acute stroke unit | 115 (84%) |
| Neurorehabilitation unit | 14 (10%) |
| Geriatric rehabilitation | 8 (6%) |
*Very inexperienced, EFFECTS was their first trial
**Quite experienced. Involvement in two or three studies during the past 5 years
***Very experienced. Involvement in five or more studies during the past 5 years or conducted their own research
Fig. 3participant flow diagram
To succeed with inclusion in a randomised controlled trial
| Factors in questionnaire | n | % |
|---|---|---|
| Relevant question | 124 | 97 |
| Consent procedure is simple | 118 | 92 |
| Support team responds quickly to any questions | 113 | 89 |
| Local principal investigator is highly engaged | 112 | 87 |
| Research nurse is highly engaged | 111 | 87 |
| Follow-ups are simple and can be coordinated with the clinical follow-up | 111 | 87 |
| Involvement in the trial is fun | 107 | 84 |
| Regular contact between the main centre and the local centre | 102 | 80 |
| Those leading the trial are very enthusiastic | 101 | 79 |
| Regular information, digital newsletters or website updates | 85 | 66 |
| Regular investigation meetings | 67 | 53 |
| Regular nursing meetings | 65 | 51 |
| The trial is academic-driven | 63 | 50 |
| My centre includes many patients or participants in the trial | 50 | 39 |
| Basic compensation (e.g. cinema voucher) | 44 | 34 |
| Well-known researchers in the steering committee | 27 | 21 |
n denotes the number of alternatives 4 and 5 on a Likert scale: 1 (completely disagree), 3 (partially agree) and 5 (completely agree)
Patient-related barriers
| Factors in questionnaire | n | % |
|---|---|---|
| Fear of side effects | 45 | 35 |
| Language problems | 39 | 30 |
| Difficulties in understanding the importance of randomising | 25 | 20 |
| A fear of not receiving the best possible treatment | 15 | 12 |
n denotes the number of alternatives 4 and 5 on a Likert scale: 1 (completely disagree), 3 (partially agree) and 5 (completely agree)
Centre-related barriers
| Factors in questionnaire | n | % |
|---|---|---|
| Lack of time and resources | 92 | 72 |
| Absence of a research nurse | 40 | 31 |
| Lack of experience and organisation of research | 22 | 17 |
| Absence of a local principal investigator | 15 | 12 |
| Insufficient incentives and rewards | 14 | 11 |
| Competing trials | 11 | 9 |
| Insufficient training in the trial-specific instruments | 7 | 5 |
| Insufficient financial compensation | 7 | 5 |
| Insufficient training in GCP | 6 | 5 |
| Concern that participation in the trial might harm the patient | 4 | 3 |
n denotes the number of alternatives 4 and 5 on a Likert scale: 1 (completely disagree), 3 (partially agree) and 5 (completely agree)
Study-related barriers
| Factors in questionnaire | n | % |
|---|---|---|
| Narrowly defined criteria for inclusion and exclusion | 40 | 31 |
| That inclusion is not a simple process | 22 | 17 |
| Comprehensive monitoring | 16 | 12 |
| Weak and unclear organisation by those leading the trial | 14 | 11 |
| The regulations for clinical trials | 10 | 8 |
n denotes the number of alternatives 4 and 5 on a Likert scale: 1 (completely disagree), 3 (partially agree) and 5 (completely agree)